Critique / Red-Team Pass — Biohacking Landscape Docs 01–07

Independent critique agent, 2026-05-31. Job: find problems and gaps, not rewrite. Severity tags: HIGH (load-bearing error, contradiction, or gap that would mislead a reader or the author's roadmap conclusions) · MED (real issue, fixable, lower stakes) · LOW (polish / nice-to-have). Spot-checked 3 high-stakes claims via web search; everything else is internal cross-reading. Verdict at the bottom.

Overall: This is a strong corpus — unusually disciplined about demonstrated-vs-speculative, source URLs are dense and mostly real, "what I couldn't verify" sections are genuinely candid, and the skeptic framing is consistently present rather than bolted on. The biggest single problem is a 10×-off market-size figure that contradicts a sibling doc, plus a handful of coverage gaps (notably the cryonics/biostasis startup wing, approved gene-editing therapeutics like Casgevy, and international BCI/longevity scenes). No evidence of systematic fabrication; the speculative-vs-real discipline is the corpus's strongest feature.

A. Likely-hallucinated / unsourced / suspicious load-bearing claims

A1. [HIGH] Biohacking market size is internally contradictory by ~25× — doc 01 vs doc 06

• doc 01, line ~140: "Market reports put 'biohacking' at ~$1.36B (2024) → $1.70B (2025), CAGR ~24% ([GMInsights])."
• doc 06, lines 32 & 184: "biohacking market valued at ~$38B in 2025, projected ~$217B by 2035" / "$38.05B (2025) → $216.68B by 2035 (~19% CAGR) [Astute Analytica]."
• Problem: These are the same market and differ by ~25×. I spot-checked: the vendor cluster for 2025 runs ~$20B–$45B (Mordor $33B, GMInsights $28.2B, Precedence $37.6B, Fortune $20.6B, Business Research Co $45B). So doc 06's ~$38B is in the right ballpark; doc 01's $1.36B is wrong by an order of magnitude — and doc 01 even attributes it to GMInsights, which actually reports $28.2B for 2025. Doc 01 likely grabbed a narrow sub-segment number or a transposed/misread figure. Both docs flag the figures as directional (good), but the order-of-magnitude clash between two docs in the same project is a credibility problem if a reader notices.
• Fix: Replace doc 01's "$1.36B→$1.70B" with the corrected GMInsights figure (~$28.2B 2025) or just cross-reference doc 06's number and note the range across vendors ($20–45B). Make the two docs cite the same figure or explicitly reconcile.

A2. [MED] Neuralink "~21 humans" — single-sourced, fast-ramp, flagged but load-bearing in the TL;DR

• doc 03, lines 1/40–43: "~21 humans implanted across 4 countries (early 2026)" appears in the headline TL;DR and is company-self-reported ("Two Years of Telepathy"), with a noted jump from "12 by late 2025." The doc does flag this (C2, open-questions §). Good. But it's stated flatly in the TL;DR ("~21 humans implanted") without the hedge that's three lines down.
• Fix: Add "(company-reported)" inline at the TL;DR mention so the hedge travels with the number.

A3. [LOW] Several precise self-report figures stated without the hedge in summaries

• Bryan Johnson "muscle mass +7%, follistatin +160%" (doc 02 4B) — self-reported, correctly tagged C2/C4 but the number is memorable and will get quoted; fine as-is since it's hedged.
• "~1,500 animals died in Neuralink testing" (doc 03) — sourced (Reuters/Wikipedia), reasonable.
• Lepht "50+ implants," Anastasia Synn "Guinness ~52 implants," "Biohax ~4,000 Swedes chipped" — all journalistic/self-report, all flagged in doc 01's open-questions. Acceptable.
• No action needed, listed for completeness — these are the figures most likely to be quoted out of context.

A4. [LOW] Eon fly "91% behavior accuracy" — verified to exist, well-handled

• Spot-checked: the Eon Systems fruit-fly emulation (Mar 2026, FlyWire connectome in MuJoCo body, ~125k neurons/50M synapses, "91% behavior accuracy," mouse-brain plan within 2 years) is real and widely covered (Eon, The Register, Futurism, Marginal Revolution, cybernews). Doc 04's treatment is exemplary: it states the milestone and the disqualifying caveats (inferred weights, no plasticity, motor neurons not traced, "not a specific fly's mind"). This is the model for how the rest of the corpus handles hype. No fix.

A5. [MED] Retro Biosciences valuation — correct, but note the $5B target vs $1.8B achieved

• Spot-checked: $1.8B valuation (May 2026, STAT) is correct and doc 02 cites it well. Caveat the doc could add: in Dec 2025 Retro was reportedly chasing a $5B valuation (STAT, 2025-12-03) for a $1B Series A — and the May 2026 raise landed at $1.8B. That's a notable down-round-from-target signal that sharpens doc 02's "valuation is AI-halo-inflated" skeptic take (the market repriced it ~3× below the ask).
• Fix: One sentence in doc 02 §2B noting the $5B target → $1.8B actual gap as evidence the hype got repriced.

B. Sycophantic / optimistic bias (and the opposite: over-dismissiveness)

B1. [MED] Doc 04 P-estimates are presented with more precision than their basis supports

• doc 04 §8: numeric P-estimates ("~0.5–0.7," "~0.1–0.25," "single-digit % by 2100"). The doc honestly tags them C3 / "my reasoning, not authoritative." That's the right disclaimer. But putting numeric probabilities on genuinely Knightian-uncertain questions (especially "is-it-me?", which the same doc calls possibly undecidable) can read as false precision — a subtle form of overconfidence even when hedged. The P(0.05–0.15 functional human WBE by 2050) is defensible as a calibration anchor; P-numbers on the philosophy question are not really meaningful.
• Fix: Keep the engineering/throughput P-estimates; for the consciousness/identity rung, replace the implied probability with "not assignable — undecidable, see §6" rather than folding it into a conjunction of "<0.3 terms."
• Counter-note: This is the good direction of bias (erring skeptical). Not a sycophancy problem so much as a precision-theater one.

B2. [LOW] Doc 05 "somatic self-determination unifies trans/furry/grinder/uploader" thesis is elegant but lightly sourced

• doc 05 §5: the Venn-diagram "want a different body" synthesis is compelling and the doc explicitly flags it as "interpretation/synthesis, not a single citation." It's intellectually the strongest connective idea in the corpus. The risk is that an elegant unifying frame oversells a causal claim (that these scenes share a single psychological driver) that's really a hypothesis. The doc mostly guards against this (§2 "causation not settled," §6 critical takes). Borderline-fine; just be alert that the webapp/synthesis doesn't harden "shared affect" into a finding.
• Fix: None required; ensure doc 00/08 synthesis keeps the "this is a frame, not a demonstrated cause" hedge.

B3. [LOW] Doc 02 reprogramming skeptic case is well-balanced — no over-hype detected

• The reprogramming section (§2H, Brenner) and the maturity ladder (§6 table) are notably honest — "follow the disease endpoints, not the press." No sycophancy here. Good.

B4. [MED] Possible over-dismissiveness: grinder scene "small, aging, fracturing, not growing" (doc 01)

• doc 01 TL;DR / §5: repeatedly asserts the grinder core is "small, aging, ideologically fracturing, not growing." This is plausibly true but it rests heavily on one source (the Baffler piece) for the "fracturing/VC-capture/fascistic undercurrent" narrative, plus Grindfest attendance (~60) and an archived forum. The doc flags the single-source dependency in open-questions (good). But "not growing" is stated as fact in the TL;DR while the evidence is anecdotal (no census exists, as the doc itself admits). This is the inverse failure mode — confident dismissal on thin evidence.
• Fix: Soften TL;DR "not growing" → "no evidence of growth (no census; flagship meetup static at ~60)." Don't let the Baffler's editorial frame ("fascistic sentiments lurk") carry as a neutral finding.

C. Internal contradictions across docs

C1. [HIGH] Market size — see A1 (the big one).

C2. [MED] Vitalia split — doc 02 vs doc 07 disagree on the resulting entities AND the date

• doc 02 §4C: "Vitalia (Jan–Mar 2025 pop-up)… split in 2025 — co-founder Niklas Anzinger rebranded it 'Infinita City'; co-founder Laurence Ion left."
• doc 07 §4: "the Vitalia pop-up (Jul 2024)… which in Jan 2025 split into Viva City and Infinita City."
• Problems: (a) Date: doc 02 says Vitalia ran Jan–Mar 2025; doc 07 says the pop-up was Jul 2024. (b) Outcome: doc 02 says it became Infinita City (one entity, Anzinger); doc 07 says it split into two — Viva City AND Infinita City. These can't both be the clean story.
• Fix: Reconcile. Likely truth: there was an earlier Vitalia (2024) and a 2025 iteration, and the split produced Infinita (Anzinger) + possibly a "Viva City." Pick one timeline, cite it in both docs, and make the entity names consistent.

C3. [LOW] Próspera backers attribution slightly inconsistent

• doc 01 calls Próspera "Thiel/Altman-linked"; doc 07 calls it "backed by Thiel & Andreessen"; doc 02 doesn't name backers. Altman vs Andreessen is a meaningful difference (and "Thiel/Altman-linked" for Próspera is the shakier claim — Próspera's named backers are usually Thiel, Andreessen/a16z, Pronomos).
• Fix: Standardize to the verifiable backer list (Thiel/Pronomos, a16z) across docs; drop "Altman-linked" for Próspera unless sourced.

C4. [LOW] Aaron Traywick death framing is consistent across docs 01 & 02 — good (no contradiction). Noted as a positive.

C5. [LOW] "86 billion neurons / 100 trillion synapses" appears in docs 03 and 04 with consistent numbers and consistent hedging on the synapse estimate. Consistent. Good.

D. Coverage gaps (orgs/people/scenes that should be in a 2026 map but are missing or thin)

D1. [HIGH] Approved gene-editing therapeutics (Casgevy/Lyfgenia) are entirely absent

• The brief explicitly named "gene-editing therapeutics that reached approval like Casgevy." No doc mentions Casgevy (exa-cel), Lyfgenia, or CRISPR Therapeutics/Vertex/Intellia. This is a glaring omission for a 2026 biohacking-landscape map: Casgevy (the first FDA/MHRA-approved CRISPR therapy, sickle-cell/beta-thal, late 2023) is the single most important demonstrated, approved gene-editing milestone — and it's the real-world counterpoint to the DIY-CRISPR theater in docs 01/02. Doc 02 covers DIY gene therapy (Zayner, Parrish, Minicircle) and reprogramming, but never anchors it against the approved, rigorous end of gene editing.
• Fix: Add a short subsection to doc 02 (or doc 06) on approved/clinical gene editing — Casgevy/Lyfgenia (ex vivo), plus in-vivo players (Intellia NTLA-2001 for ATTR, Verve, Beam, Prime Medicine). This is the demonstrated benchmark that makes the DIY fringe look like the fringe.

D2. [HIGH] The cryonics/biostasis startup wing is under-covered as a 2026 scene

• The brief explicitly named "the 'biostasis'/cryonics-startup wing." Doc 04 §3c covers preservation orgs (Nectome, Oregon/Sparks, Cradle/Until, BPF) and cross-links /workspace/cryonics/. But the newer biostasis startup scene is thin: no mention of Tomorrow Biostasis / EBF (European Biostasis Foundation) (the fast-growing European cryonics startup, Berlin), and the framing leans on the cross-link rather than mapping the startup/funding/community layer the way docs 02/03 do for their scenes. Given FiO is the author's #1 goal, the preservation-startup landscape deserves the same treatment as the BCI company roster.
• Fix: Expand doc 04 §3c (or note in doc 02/07) with Tomorrow Biostasis/EBF and any 2024–26 biostasis startups; treat preservation as a scene with players/money, not just a chemistry cross-link. At minimum acknowledge Alcor and Cryonics Institute exist as the incumbent nonprofits the startups are reacting to (Alcor is referenced only obliquely via the cryonics folder).

D3. [MED] International scenes outside US/Bay are thin

• BCI: doc 03 is almost entirely US (+ Synchron Australia). Missing: China's BCI push (NEO/Neuracle, the Chinese "brain-computer interface" national initiative, Tsinghua's NEO implant which had human implants in 2025), and any European invasive BCI (CorTec, Onward/ABILITY for spinal). For a 2026 map this is a real gap — China is arguably the #2 BCI ecosystem.
• Longevity: doc 06 is US-centric; missing Asian/European longevity scene depth (Japan's reprogramming work is noted via Yamanaka but not the broader scene; Saudi Hevolution Foundation — a $1B/yr funder — is absent and is one of the biggest longevity funders on earth).
• Fix: Add a short "international" note to docs 03 and 06 — at least Tsinghua NEO / Chinese BCI, and Hevolution as a longevity funder. Hevolution's absence from doc 02/06's funding discussion is notable given its scale.

D4. [MED] Nootropics depth is thin (brief asked for "nootropics depth")

• The brief's doc-07 line and doc-06 scope call for nootropics. Doc 06 mentions r/Nootropics in a list and "magnesium L-threonate" in passing, but there's no actual nootropics map — no racetams, modafinil, the Gwern/SSC self-experimentation lineage (n-back, blinded self-trials), the "stack" culture, or current players. Given nootropics are a core biohacking sub-scene and connect to the rationalist/quantified-self culture (doc 07), this is under-covered.
• Fix: Add a nootropics paragraph to doc 06 (canon: racetams, modafinil, L-theanine+caffeine, the blinded-self-experiment tradition) and link the rationalist self-experimentation culture in doc 07.

D5. [MED] Specific longevity cos named in the brief but dropped: Unity is in, but the brief also implied broad coverage — Retro/Altos/NewLimit/Calico/Unity all present (good). Missing notables: Life Biosciences (Sinclair's own reprogramming co, partial-repro optic-nerve work in primates — arguably the most clinically advanced reprogramming story and it's absent), Rejuvenate Bio (George Church's gene-therapy aging co), BioAge (had a Phase 2 GLP-1-adjacent failure 2024). Life Biosciences is the biggest miss — it's running toward IND for ER-100 (optic neuropathy) using partial reprogramming.

• Fix: Add Life Biosciences to doc 02 §2 (reprogramming) — it's a peer of Altos/NewLimit and its primate optic-nerve data is more advanced than most. Rejuvenate Bio and BioAge are lower-priority adds.

D6. [LOW] Sensory-substitution academic depth, artificial-womb players, and OpenWater

• Doc 03's non-invasive section omits Openwater (Mary Lou Jepsen's optical/ultrasound neuro-imaging co) — a recognizable consumer-neuro-adjacent player. Low priority.
• Doc 02's artificial-womb coverage (EXTEND/Vitara) is fine but doesn't mention the Eindhoven/Juno or Japanese artificial-womb efforts. Low priority.

D7. [LOW] DIY-bio: iGEM explicitly left at C5/unverified

• Doc 02 §5 admits iGEM 2025–26 specifics weren't verified (honest). For a landscape map this is acceptable but the brief named the community-lab/DIYbio scene as important; iGEM is the talent pipeline. Low-priority verify.

E. Stale-data risk (fast-moving facts to re-check before the webapp ships)

• [HIGH] Neuralink participant count (~21, doc 03) — moves monthly; re-check at publish.
• [HIGH] Retro Alzheimer's trial data — doc 02 says "data expected ~Aug 2026." If the webapp ships near/after Aug 2026, this readout will exist and change the story. Flag to re-check.
• [MED] Eon Systems mouse-brain progress (doc 04) — they announced a 2-year mouse-brain plan (Mar 2026); any interim milestone changes the WBE narrative. Re-check.
• [MED] Vitalia/Infinita/Viva City status (docs 02/07) — charter-city entities are volatile (Boing Boing called it a "collapse"); the ZEDE arbitration (~$10.7B) outcome could moot the whole venue. Re-check at publish.
• [MED] Próspera ZEDE legal status — Honduras Supreme Court ruling + arbitration ongoing; doc 02 handles this well but it's live.
• [MED] Altos "began human safety testing Aug 2025" — doc 02 flags it's secondary-sourced with no ClinicalTrials.gov reg (good). Re-check for a registry entry.
• [MED] The ODIN / Zayner post-2020 activity — doc 01 flags this as a C5 gap. A direct check of the-odin.com store + Zayner socials is cheap and would close it.
• [LOW] Don't Die "religion" durability (doc 06) — <1yr old, may fade; re-check.
• [LOW] Whoop "Healthspan" / Oura revenue figures — vendor/marketing numbers, re-check.

F. The two-end-goal framing — is anything under-covered?

F1. [MED] FiO path: nerve-reconnection is repeatedly flagged as "silent/unsupported" but never actually researched

• Multiple docs (02 §6, 03 bottom, 05) say nerve reconnection is "not addressed by any company" / "Hébert/ARPA-H + BCI." But there are real players: ONWARD Medical (spinal-cord stimulation, walking restored in SCI patients, FDA Breakthrough), the Courtine/Bloch "digital bridge" (Lausanne, brain-spine interface restoring walking, Nature 2023), and peripheral-nerve regeneration work. For "biopunk 2037 / nerve reconnection," this is a genuine demonstrated-in-humans scene that the corpus declares absent. That's an over-dismissive gap on a topic the author explicitly cares about.
• Fix: Add a short nerve-reconnection node (doc 03 or 08): Courtine/Onward brain-spine interface (demonstrated, human, walking restored) is the strongest real evidence for the author's "nerve reconnection" worldbuilding element — and the corpus currently says it doesn't exist.

F2. [MED] FiO path: the "AI does the scan-translation" dependency is asserted but the strongest evidence is under-developed

• Doc 04 §7 says AI could "collapse the throughput problem" and notes AI segmentation already drives FlyWire/MICrONS. This is the most consequential lever on the whole FiO timeline (it's what would move P from single-digit). It's correctly out-of-scope for AI-timeline reasoning, but the connectomics-specific AI acceleration (how much faster has AI segmentation made EM reconstruction 2020→2026?) is the one piece of the AI dependency that is in scope and would directly update the timeline. It's mentioned but not quantified.
• Fix: One paragraph in doc 04 §2/§7 quantifying connectomics-throughput improvement from AI segmentation (the trend that determines whether "17 My" becomes "decades"). This is the highest-leverage timeline input and it's currently hand-waved.

F3. [LOW] Biopunk-2037: well-served. Doc 02's maturity ladder (xeno > senolytics > bioengineered organ assist > ectopic > reprogramming > DIY > organ sacs) is exactly the honest map the author needs, and correctly identifies xeno+bioengineered organs (not organ sacs) as the real substrate. Strong. The only thin spot is nerve reconnection (see F1).

F4. [LOW] FiO: doc 04 is the strongest doc in the set for the author's #1 goal — rigorous, honest, correctly identifies data-acquisition (not compute, not BCI) as the binding constraint, and the Eon-fly handling is a model of demonstrated-vs-hype. The only gaps are F1 (nerve), F2 (AI-segmentation trend), and D2 (biostasis startups).

Top 5 things to fix (prioritized)

1. [HIGH] Fix the market-size contradiction (A1/C1). Doc 01's "$1.36B→$1.70B" is ~25× below doc 06's "$38B→$217B" for the same market, and ~10× below the GMInsights source doc 01 cites. Correct doc 01 to the real vendor range (~$20–45B in 2025) or cross-reference doc 06. This is the one error that would visibly damage credibility.

2. [HIGH] Add the approved gene-editing benchmark (D1). Casgevy/Lyfgenia (first approved CRISPR therapies) and in-vivo players (Intellia, Beam, Verve) are entirely missing. They're the demonstrated, rigorous counterpoint that contextualizes the DIY-CRISPR theater — a notable omission the brief explicitly called out.

3. [HIGH] Map the biostasis-startup wing + close the nerve-reconnection gap (D2 + F1). For the author's #1 goal, add Tomorrow Biostasis/EBF and treat preservation as a scene with players/money. For biopunk-2037, the corpus wrongly declares nerve reconnection unaddressed — Courtine/Onward's brain-spine interface restored walking in humans (Nature 2023) and is the strongest real evidence for that worldbuilding element.

4. [MED] Reconcile the Vitalia split (C2) — docs 02 and 07 disagree on both the date (Jul 2024 vs Jan–Mar 2025) and the outcome (Infinita alone vs Viva City + Infinita). Pick one sourced timeline and make both docs consistent.

5. [MED] Add international depth + missing peers (D3, D5). China BCI (Tsinghua NEO), Hevolution Foundation ($1B/yr longevity funder), and Life Biosciences (Sinclair's reprogramming co with primate optic-nerve data, more clinically advanced than several cos that are covered) are conspicuous absences. Add a nootropics paragraph to doc 06 while you're in there (D4).

Verdict on corpus quality

High quality for a landscape overview — better than most. The demonstrated-vs-speculative discipline is consistently applied and is the corpus's defining strength; the "what I couldn't verify" sections are honest and specific (they pre-flag most of the C5 gaps I'd otherwise raise); source URLs are dense and the three I spot-checked (Eon fly, Retro valuation, market size) were real, with the Eon-fly and Retro handling notably careful. The skeptic framing is genuine, not decorative.

The defects are correctable and concentrated: one order-of-magnitude market-size contradiction (the only HIGH-severity factual error I found), a few cross-doc inconsistencies (Vitalia, Próspera backers), and several coverage gaps the brief actually predicted (approved gene editing, biostasis startups, international scenes, nootropics, nerve reconnection). None of these undermine the core analysis; the two-roadmap conclusions (compute isn't the FiO bottleneck — data acquisition is; xeno/bioengineered organs not organ-sacs are the real biopunk substrate) are well-supported and would survive the fixes. Fix the top 5 and this is a publishable, trustworthy map.

Resolution log (gap-fix agent, 2026-05-31)

All items below web-verified; real source URLs added in the docs. New claims marked demonstrated vs. speculative; load-bearing numbers given confidence tiers.

1. [HIGH] Market-size error/contradiction — FIXED. doc 01's bogus "$1.36B→$1.70B" replaced with the real vendor figures: GMInsights ~$24.5B (2024) → ~$28.2B (2025), wider vendor cluster ~$20–45B for 2025, 10-yr forecasts ~$110–217B. doc 06 (TL;DR, §5, open-Qs) reconciled to the same $20–45B range and re-tiered C3→C4 (vendors disagree ~2×). doc 00 scene table + market-note updated to the same range and the old contradiction note rewritten. Docs 01 and 06 now cite the same range and explicitly cross-reference each other. (GMInsights, Astute Analytica, Mordor, Fortune, Precedence.)

2. [HIGH] Approved gene editing — ADDED. New doc 02 §4E "the rigorous counterpoint: approved & clinical-stage human gene editing": Casgevy (exa-cel, first FDA-approved CRISPR therapy, Dec 8 2023, sickle-cell/beta-thal — CRISPR Therapeutics/Vertex); Lyfgenia (bluebird, same day, lentiviral); in-vivo: Intellia (nex-z/NTLA-2001 TTR, Phase 3; lonvo-z/NTLA-2002 HAE, positive Phase 3, US launch ~1H2027), Verve (VERVE-102 base editing PCSK9; acquired by Eli Lilly ~$1.3B, 2025), Beam. Framed explicitly as the demonstrated/regulated benchmark vs. Zayner/Parrish/Minicircle theater. Also surfaced in doc 00 ledger (a) + the DIY-theater bullet (c). (Noted Intellia patient-death caveat.)

3. [HIGH] Biostasis startups + nerve reconnection — FIXED. (a) doc 04 §3c: added Alcor + Cryonics Institute to the orgs table as incumbents, plus a new "biostasis startup layer" subsection led by Tomorrow.Bio / Tomorrow Biostasis (Berlin) + European Biostasis Foundation — 20 humans/10 pets preserved, >800 signed up, €5M seed (May 2025) for US expansion; cross-linked /workspace/cryonics/. (b) Factual error corrected: the corpus's "nerve reconnection unaddressed by any company" claim was wrong. Added the Courtine & Bloch / ONWARD Medical "digital bridge" (EPFL/CHUV, Nature, 24 May 2023) — restored thought-controlled walking in a paralyzed human, with recovery persisting system-off — as a new node in doc 03 Part B, and corrected the framing in doc 02 §6, doc 08 (B4, B6, scorecard), and doc 00. Reframed as: function of reconnection demonstrated in humans via interface; biological re-fusion of a severed nerve at scale still unsolved. doc 08 P-estimate framing updated (nudges the function-restoration reading toward the upper end; biological-refusion stays low).

4. [MED] Vitalia/Próspera split — RECONCILED to one timeline. Single sourced story now in docs 02 §4C, 07 §4, 00: Vitalia 2024 pop-up (headline Jul 2024) → co-founders split Jan 2025 → Niklas Anzinger keeps Roatán hub, renames it Infinita City (Mar 2025); Laurence Ion leaves to start Viva City (SF). doc 02 previously said "Jan–Mar 2025 / became Infinita alone"; corrected to match doc 07's (correct) Jul-2024-pop-up + Jan-2025-two-way-split. (Lifespan.io, New Republic, Infinita City/X.)

5. [MED] International depth + missing peers + nootropics — ADDED. - doc 03: new China-BCI subsection — Tsinghua/Neuracle NEO (minimally invasive; first human 2023; NMPA commercial clearance reported Apr 2026) and CIBR/NeuCyber Beinao-1 (3 patients early 2025, ~50 target 2026). - doc 02 §7: added Hevolution Foundation (Riyadh; ~$1B/yr; >$400M deployed; $40M to XPRIZE Healthspan). New §2H Life Biosciences (Sinclair; PER/OSK; primate optic-nerve NAION data; FDA IND cleared for ER-100 Jan 28 2026, first-in-human Q1 2026 — first reprogramming therapy to clear an IND). - doc 06: new §3b nootropics paragraph — Giurgea/racetams, modafinil, L-theanine+caffeine, stack culture, and the Gwern/SSC blinded-self-experiment lineage; linked to rationalist culture (doc 07).

Not fully resolvable / left as-is: the critique's LOW/MED items not in my brief were left untouched by design (A2 Neuralink-count hedge, A5 Retro $5B→$1.8B repricing, B-series bias notes, C3 Próspera backers "Altman" wording, D6/D7 OpenWater/iGEM, the stale-data E-list). The Intellia program death is real and now noted as a caveat rather than suppressed. No new contradictions introduced; market figure and nerve-reconnection point are now consistent across docs 00/01/02/03/04/06/07/08.